Overview

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

Status:
Withdrawn
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide
Sitagliptin Phosphate